High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.

Abstract

Resistance to the novel β-lactam/β-lactamase inhibitor combination ceftazidime-avibactam (CAZ-AVI) among carbapenem-resistant Enterobacteriaceae (CRE) has infrequently been reported in the United States. We report unexpectedly high rates of resistance to CAZ-AVI in CRE bloodstream isolates at our institution associated with the nonoutbreak spread of New Delhi metallo-β-lactamase in diverse Enterobacteriaceae species.

• Authors: Samuel L Aitken, Jeffrey J Tarrand, Lalitagauri M Deshpande, Frank P Tverdek, Anne L Jones, Samuel A Shelburne, Randall A Prince, Micah M Bhatti, Kenneth V I Rolston, Ronald N Jones, Mariana Castanheira, Roy F Chemaly
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 63 Issue 7 Pg. 954-958 (10 01 2016) ISSN: 1537-6591 [Electronic] United States
• PMID: 27313265 (Publication Type: Journal Article)
• Copyright: © The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail [email protected].

Chemical References

• Anti-Bacterial Agents
• Azabicyclo Compounds
• Drug Combinations
• avibactam, ceftazidime drug combination
• Ceftazidime
• beta-Lactamases
• beta-lactamase NDM-1

Topics

• Adult
• Aged
• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Azabicyclo Compounds (pharmacology, therapeutic use)
• Bacteremia (drug therapy, epidemiology, microbiology)
• Cancer Care Facilities
• Ceftazidime (pharmacology, therapeutic use)
• Child, Preschool
• Drug Combinations
• Drug Resistance, Bacterial
• Enterobacteriaceae (drug effects, enzymology, genetics)
• Enterobacteriaceae Infections (drug therapy, epidemiology, microbiology)
• Female
• Humans
• Male
• Middle Aged
• Young Adult
• beta-Lactamases